More payers are trying to rein in the use of antipsychotics in patients WITHOUT psychotic disorders

December 2013

More payers are trying to rein in the use of antipsychotics in patients WITHOUT psychotic disorders.

Almost $6 BILLION a year is spent on Abilify alone.

Now the Choosing Wisely report and others are pointing out when the risks of antipsychotics are likely to outweigh their benefit.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote